Search results
Results from the WOW.Com Content Network
For AbbVie, the 200-day moving average sits at $176.24, according to Benzinga Pro, which is below the current price of $189.49. For more on charts and trend lines, see a description here.
In the news release about the trial, AbbVie's chief scientific officer Roopal Thakkar said that the company is still "committed to finding better treatments for people living with psychiatric and ...
It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big ...
AbbVie reported earlier this month that Humira's U.S. sales plunged by 35% to $12.16 billion last year, but said it expected the drug to maintain broad insurance coverage in 2024, which would help ...
AbbVie has retained most of the U.S. market for Humira this year, despite the launch of 10 biosimilar alternatives to the drug since January 2023 from companies including Pfizer.
AbbVie has offered $31.26 per share in cash, representing a premium of 94.6% to Immuogen stock's last close. Immunogen's shares surged 82% to a near 23-year high of $29.34 in early trading.
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The company said it will ...
AbbVie has also agreed to pay Landos shareholders an additional up to $11.14 per share, or around $75 million in total, contingent on certain clinical development milestones.